Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
UCSF - sulbactam/durlobactam renal and HD regimens
Product / population
Adult IV sulbactam/durlobactam; restricted to infectious-disease/antimicrobial-stewardship approval for carbapenem-resistant Acinetobacter infections.
Renal method
CrCl, mL/min.
Source revision
Revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Exact-130 threshold differs between printed sources
At CrCl exactly 130 mL/min, the printed UCSF band uses a six-hour interval; the official label places 130 in the four-hour band.
What to reconcile: Do not average these intervals. Confirm current labeling and the local protocol before clinical use.
Source difference identified; final patient-specific adjudication required.
UCSF Infectious Diseases Management Program · Adult IV sulbactam/durlobactam; restricted to infectious-disease/antimicrobial-stewardship approval for carbapenem-resistant Acinetobacter infections.
Renal method: CrCl, mL/min. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Each 2 g dose is sulbactam 1 g plus durlobactam 1 g.
CrCl
Combined IV dose
Above 130
2 g every 4 hours
45-130
2 g every 6 hours
30-44
2 g every 8 hours
15-29
2 g every 12 hours
Below 15
2 g every 24 hours
For a new start below 15, give 2 g every 12 hours for three doses before the once-daily regimen. Intermittent HD: 2 g every 12 hours for three doses, then 2 g every 24 hours; doses are given after HD. Continuous-hemodialysis data are not provided. Infusion preparation/duration and the rest of the combination-treatment protocol require the complete prescribing and institutional guidance.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.